Compass Pathways Stock

Compass Pathways Liabilities

The The Liabilities of Compass Pathways (CMPS) as of Sep 4, 2026 is 263.20 M USD. In the previous year, The Liabilities was 58.97 M USD — a change of 346.32% (higher).

Liabilities

263.20 MUSD

YoY

346.32%

Last updated:

In 2026, Compass Pathways's total liabilities amounted to 263.20 M USD, a 346.32% difference from the 58.97 M USD total liabilities in the previous year.

The Compass Pathways Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
40.75 M USD
Jan 1, 2019
23.87 M USD
Jan 1, 2020
6.90 M USD
Jan 1, 2021
16.49 M USD
Jan 1, 2022
16.01 M USD
Jan 1, 2023
50.24 M USD
Jan 1, 2024
58.97 M USD
Jan 1, 2025
263.20 M USD
The Compass Pathways Liabilities history
YEARLiabilitiesYoY
263.20 MUSD+346.32%
58.97 MUSD+17.37%
50.24 MUSD+213.74%
16.01 MUSD-2.86%
16.49 MUSD+139.10%
6.90 MUSD-71.12%
23.87 MUSD-41.43%
40.75 MUSD
Access this data via the Eulerpool API

Compass Pathways Stock analysis

What does Compass Pathways do? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Compass Pathways's Liabilities

Compass Pathways's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Compass Pathways's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Compass Pathways's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Compass Pathways's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Compass Pathways’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Compass Pathways stock

The Liabilities of Compass Pathways is 263.20 M USD in 2026.

The Liabilities of Compass Pathways changed from 58.97 M USD to 263.20 M USD, representing a 346.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Compass Pathways since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Compass Pathways historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Compass Pathways

All Key Metrics — Compass Pathways